


Diabetes and the Eye

MB Ch B IV Lecture- 8th February, 2016, University of Nairobi, LT III



Dr Nyamori JM


M.bchB, Mmed-ophth, University of Nairobi, FEACO
Medical & Surgical Retina, University of Calgary, Ab, CA

Outline: Diabetic Eye Disease

- Epidemiology
- Anterior Segment: Conjunctiva-Cornea-Lens
- Posterior segment:
 - Investigations
 - Diabetic Retinopathy & Maculopathy
- Clinical case examples, evidence-based
- Screening


Epidemiology-Diabetic Eye Disease

- Globally
 - Most prevalent cause of legal blindness among 20-65 years
- Kenya
 - Population= 45 million
 - 22m are age 20-79yrs
 - Diabetics= **840,000**
 - Prevalence=3.6
 - Retinopathy=**268,000**
 - Vision Threatened=**84,000**




A. Conjunctiva/Cornea: Dry Eye Syndrome

- Meibomian gland dysfunction
- ↓Corneal sensitivity
- Neuropathy involving nerves to lacrimal glands
- Loss of goblet cells




B. Cornea Epithelium: Defects

- Persistent epithelial defects
 - Reduced formation of desmosomes and anchoring fibrils at basement membrane
- Corneal ulcers increased risk
 - Poor wound healing
 - Viral: HSV



C. Lens: Cataract

1. Glucose → sorbital retained → Cataract.
2. Glycosylation of lens proteins



D. Diabetic Retinopathy

Retinal vessels are affected by hyperglycemia.

Prevalence:

- Type 1 DM: Rare at diagnosis...90% at 15 yrs.
- Type 2 DM: 20% at diagnosis...60% at 15 yrs.


...therefore physician should **refer diabetics to the eye clinic**

Investigations: Retina Imaging for Diabetes


- **Optical Coherence Tomography, Retina scan**
- **Cameras: Photo, Angiography**



1. Optical Coherence Tomography(OCT) scan






OCT-Normal Macular



OCT-Macular Oedema

2. Camera: Fluorescein Angiography



- **Standard: 50⁰, 7 field EDTRS 75⁰**

- **Miss** periphery
- Montages need expertise
- Patient gaze-control
- Must dilate

- **Optos 200TX UWF™: 200⁰**

- Ultra wide field, **>80%** retina
- Photo/auto/angio-graphic
- 0.25s, 14um, **friendly** single-shot
- Non-mydriatic, non-contact

Risks For Diabetic Retinopathy

- ↑ **Long duration** of DM
- **Poor glycemic control**

Other:



- Hypertension
- Hypercholesterolaemia
- Severe nephropathy
- Pregnancy
- Obesity

Pathogenesis: 1. IRMA

- Small vessel **Occlusion**, Intraretinal microangiopathy (IRMA)



- Cotton wool spots: infarcts of retinal Nerve Fibres

“the pipes are blocked... no flow”




Pathogenesis: 2. Microvascular leakage

- Breakdown of vessel wall → microaneurysms, bleeding, exudates, edema
- *“the pipes are leaking ...wet everywhere”*



Pathogenesis: 3. Haemorrhages

- *“blood escapes outside the pipes(capillaries)”*



Pathogenesis: 4. Neovascularization

- “Abnormal fragile new vessels growth” due to angiogenic factors (VEGF)



Stages of diabetic retinopathy


Importance of staging:

- Severity: Mild-Moderate-Severe.
- Risk for visual loss and cardiovascular
- Management and Follow-up

A. Non-Proliferative Diabetic Retinopathy (NPDR)


- **Mild:**

- Microaneurysms (MAs)
- Review every **9-12 months**




- **Moderate:**

- MAs, dot/blot hemorrhage, hard exudates, CWS.
- Review **6 monthly** (16% progress to PDR in 4yrs)



NPDR continued...

- **Severe NPDR, 4-2-1 rule**
 - 4 quadrants **hemorrhages**
 - Or ≥ 2 quadrants venous **beading**
 - Or ≥ 1 quadrant **IRMA**.
- *75% progress to PDR within 1 year



- **Rx: LASER is useful (DRS study)**


- **Very severe:** 2 of the 4-2-1

- Rx: LASER panretinal



B. Proliferative Diabetic Retinopathy

Subhyaloid Hemorrhage




Traction Retinal detachment:
Vitrectomy surgery




New vessels on the Iris, pupil



Vision Threatening Retinopathy: Rx Laser



Laser Panretinal Photocoagulation (PRP)




Therapy for Iris Neovascularization

1. Laser Pan Retinal Photocoagulation (PRP)


2. Treat **Neovascular glaucoma**:

- PRP +/- Drainage device eg Ahmed Valve.



Therapy for Vitreous haemorrhage

- Laser-PRP
- Ocular Ultrasound + wait
- If persistent eg 3 months:
Vitrectomy + endolaser



Diabetic Maculopathy

- DME introduction video...




E. Diabetic Maculopathy

- Most common cause of visual impairment in Diabetes

Classification:


- **Focal** edema/exudates
- **Diffuse** edema
- **Ischaemic**

Diabetic maculopathy



Diabetic maculopathy-pathogenesis

- Oedema, exudates, or ischaemia are mediated by:
 - Vascular Endothelial Growth factor (**VEGF**)




Management of Maculopathy

- Focal oedema: Focal **laser**.
- Diffuse oedema: Grid **laser**.
- Macula Centre edema:
 - **Never laser the fovea !**
 - **Intravitreal Anti-VEGF or Triamcinolone (Kenalog)**
- Ischaemic maculopathy: No role for laser.




Current Management – Diabetic Maculopathy

- Standard care has shifted **from laser to Anti-VEGF injections**
 - **Intravitreal Steroids** cause cataract, glaucoma, floaters



The Anti-VEGF medication

Pegaptanib



Aptamer

Binds specifically only one VEGF-A isoform

Bevacizumab*



Monoclonal antibody

Binds all VEGF-A isoforms

Ranibizumab



Antibody fragment

Binds all VEGF-A isoforms with a higher affinity than bevacizumab

Aflibercept



Fusion protein

Binds VEGF-A with higher affinity than bevacizumab and ranibizumab¹
Also binds VEGF-B and PlGF

2004

2005

2006

2011

2013

Bevacizumab





- Avastin:
 - Usually for Cancer of the colon
 - “Off label” for retina
 - Tachyphylaxis, **Endophthalmitis risk**
- Fewer Trials

Ranibizumab (Lucentis)




- **FDA approved intravitreal**
 - Sterile solution assured
 - Safety, Efficacy in most Trials
 - Treat and extend vs Fixed monthly dose
- Gold Standard eg N.America
- Also for Age related Macular degeneration



RESTORE study: Lucentis Efficacy

Teamwork: Learning Point

- Differential Diagnosis: Diabetes with comorbidity
- Role of **Angiography** and **Multidisciplinary** approach



Diabetes Retinopathy: Studies in Kenya

	DR	CSME	FUNDOSCOPY	LASER
Kariuki et al 1999 (KNH)	49.8%	40.3%	18%	0%
Wambugu et al 2011 (KNH)	31.9%	8.5%	47.2%	5.5%
Kibata et al (Rural)	18.3%	4.5%		

↑ DR with ↑ BP.

↑ DR with ↑ HbA1c (not statistically significant).

Assoc with Duration/BP/Total Chol


Diabetic Screening

- Diabetic Patient population




- Doctors clinics

Role of Physician-Ophthalmologist Collaboration



Role of Physician/MO/Intern

- Send all diabetics to Eye clinic for screening, annually
 - Do not wait for Eye symptoms, HbA1c, Fasting Blood Sugar
- Same-day funduscopy/camera photography



Where to refer your Diabetics for eye exam?

- Nearest Ophthalmologist
- Public Retina Clinics:
 - Public: KNH, University Of Nairobi
 - Kikuyu eye Unit, Nairobi
 - Sabatia eye Hospital, Vihiga
 - Tenwek Hospital, Bomet
 - Lions eye Hospital, Loresho
- Private Retina Specialists:
 - Few <10, most in Nairobi



Role of ophthalmologist

- **Screen** and **treat** diabetic eye disease: LASER, Injections
- **Refer/update** physician on retinopathy/risk factors
- **Attend** concurrent same-day Diabetes Medical + Eye clinics